736 related articles for article (PubMed ID: 33598864)
1. Reconsidering the Polypill for Management of Cardiovascular Risk Factors in Underserved Patients.
Macaulay TE; Sheridan E; Ward S
Curr Cardiol Rep; 2021 Feb; 23(3):19. PubMed ID: 33598864
[TBL] [Abstract][Full Text] [Related]
2. Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Muñoz D; Uzoije P; Reynolds C; Miller R; Walkley D; Pappalardo S; Tousey P; Munro H; Gonzales H; Song W; White C; Blot WJ; Wang TJ
N Engl J Med; 2019 Sep; 381(12):1114-1123. PubMed ID: 31532959
[TBL] [Abstract][Full Text] [Related]
3. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A;
Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715
[TBL] [Abstract][Full Text] [Related]
4. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
5. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.
Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD
Trials; 2011 Jan; 12():3. PubMed ID: 21205325
[TBL] [Abstract][Full Text] [Related]
6. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A;
Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727
[TBL] [Abstract][Full Text] [Related]
7. The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
Truelove M; Patel A; Bompoint S; Brown A; Cass A; Hillis GS; Peiris D; Rafter N; Reid CM; Rodgers A; Tonkin A; Usherwood T; Webster R;
Cardiovasc Ther; 2015 Dec; 33(6):347-52. PubMed ID: 26280247
[TBL] [Abstract][Full Text] [Related]
8. Strengths and Limitations of Using the Polypill in Cardiovascular Prevention.
Roy A; Naik N; Srinath Reddy K
Curr Cardiol Rep; 2017 May; 19(5):45. PubMed ID: 28425033
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial.
Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D
Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506
[TBL] [Abstract][Full Text] [Related]
10. Clinical Effectiveness of the Cardiovascular Polypill in a Real-Life Setting in Patients with Cardiovascular Risk: The SORS Study.
Castellano JM; Verdejo J; Ocampo S; Rios MM; Gómez-Álvarez E; Borrayo G; Ruiz E; Ibáñez B; Fuster V;
Arch Med Res; 2019 Jan; 50(1):31-40. PubMed ID: 31101241
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial.
Mostaza JM; Suárez-Fernández C; Cosín-Sales J; Gómez-Huelgas R; Brotons C; Araujo FP; Borrayo G; Ruiz E;
BMC Cardiovasc Disord; 2022 Dec; 22(1):560. PubMed ID: 36550424
[TBL] [Abstract][Full Text] [Related]
12. Polypill Strategy in Secondary Cardiovascular Prevention.
De la Rosa A; Arrington K; Desai R; Acharya PC
Curr Cardiol Rep; 2024 May; 26(5):443-450. PubMed ID: 38557814
[TBL] [Abstract][Full Text] [Related]
13. The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W
Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539
[TBL] [Abstract][Full Text] [Related]
14. The concept of the polypill in the prevention of cardiovascular disease.
Wiley B; Fuster V
Ann Glob Health; 2014; 80(1):24-34. PubMed ID: 24751562
[TBL] [Abstract][Full Text] [Related]
15. A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Carey KM; Comee MR; Donovan JL; Kanaan AO
Ann Pharmacother; 2012 May; 46(5):688-95. PubMed ID: 22570437
[TBL] [Abstract][Full Text] [Related]
16. PolyPill for Prevention of Cardiovascular Disease in an Urban Iranian Population with Special Focus on Nonalcoholic Steatohepatitis: A Pragmatic Randomized Controlled Trial within a Cohort (PolyIran - Liver) - Study Protocol.
Merat S; Poustchi H; Hemming K; Jafari E; Radmard AR; Nateghi A; Shiravi Khuzani A; Khoshnia M; Marshall T; Malekzadeh R
Arch Iran Med; 2015 Aug; 18(8):515-23. PubMed ID: 26265520
[TBL] [Abstract][Full Text] [Related]
17. Real-life effect on the control of risk factors associated with initiation of the cardiovascular polypill created from equipotent drugs.
Portela-Romero M; Cinza-Sanjurjo S; Conde-Sabarís P; Rodríguez-Mañero M; Mazón-Ramos P; Rey-Aldana D; González-Juanateyc JR
Rev Clin Esp (Barc); 2022 Mar; 222(3):131-137. PubMed ID: 34674985
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of Polypill for Prevention of Cardiovascular Disease (PolyPars): Protocol of a Randomized Controlled Trial.
Malekzadeh F; Gandomkar A; Malekzadeh Z; Poustchi H; Moghadami M; Fattahi MR; Moini M; Anushiravani A; Mortazavi R; Sadeghi Boogar S; Mohammadkarimi V; Abtahi F; Merat S; Sepanlou SG; Malekzadeh R
Arch Iran Med; 2020 Aug; 23(8):548-556. PubMed ID: 32894967
[TBL] [Abstract][Full Text] [Related]
19. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.
Thom S; Field J; Poulter N; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Rodgers A
Eur J Prev Cardiol; 2014 Feb; 21(2):252-61. PubMed ID: 23038750
[TBL] [Abstract][Full Text] [Related]
20. Mesoporous silica nanoparticles as a new carrier methodology in the controlled release of the active components in a polypill.
Doadrio AL; Sánchez-Montero JM; Doadrio JC; Salinas AJ; Vallet-Regí M
Eur J Pharm Sci; 2017 Jan; 97():1-8. PubMed ID: 27818251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
